Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parathyroid Carcinoma Mimicking a Parathyroid Adenoma on [18F]F-Choline-PET With Occult Metastases.

Clinical nuclear medicine·2026
Same author

Outcome-driven dosimetry optimization for [<sup>177</sup>Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization.

European journal of nuclear medicine and molecular imaging·2026
Same author

Impact of scan duration and scatter correction on quantitative accuracy in Yttrium-90 PET/CT imaging using LAFOV and SAFOV systems: a phantom and clinical evaluation.

EJNMMI physics·2026
Same author

Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.

Asian journal of urology·2026
Same author

Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.

European journal of nuclear medicine and molecular imaging·2026
Same author

Clinical Reasoning: A 55-Year-Old Man With Rapidly Progressive Weakness and Numbness.

Neurology·2026
Same journal

<sup>18</sup>F-fluorodeoxyglucose PET in Major Psychiatric Disorders.

PET clinics·2026
Same journal

Five Decades of [18F]Fluorodeoxyglucose-PET in Neuropsychiatric Disorders: From Brain Metabolism to Precision Functional Imaging.

PET clinics·2026
Same journal

Brain [18F]FDG PET in Subjective Cognitive Complaints: From Diagnostic Gap to Neurobiological Insight.

PET clinics·2026
Same journal

FDG PET in Movement Disorders and Parkinsonian Syndromes.

PET clinics·2026
Same journal

Brain [18F]FDG PET in Encephalitis and Postinfectious Neurocognitive Syndromes.

PET clinics·2026
Same journal

Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician.

PET clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2025

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.7K

Prostate-specific Membrane Antigen: Diagnostics.

Ian L Alberts1, Robert Seifert2, Rudolf A Werner3

  • 1Molecular Imaging and Therapy, BC Cancer - Vancouver, 600 West 10th Avenue, Vancouver, British Columbia V5Z 1H5, Canada.

PET Clinics
|May 3, 2024
PubMed
Summary
This summary is machine-generated.

Prostate-specific membrane antigen (PSMA)-PET/CT imaging has revolutionized prostate cancer diagnostics since 2011. This review covers common PSMA tracers and their clinical applications.

Keywords:
(18)F-PSMA-1007(68)Ga-PSMA-11ImagingPETPET/CTPSMAProstate cancerProstate-specific membrane antigen

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Related Experiment Videos

Last Updated: Jun 27, 2025

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.7K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiochemistry

Background:

  • Prostate-specific membrane antigen (PSMA) PET/CT has become a vital diagnostic tool for prostate cancer since its clinical introduction in 2011.
  • The development of novel PSMA radioligands has expanded imaging capabilities and improved diagnostic accuracy.

Purpose of the Study:

  • To provide an overview of the most frequently utilized PSMA radioligands for PET imaging in prostate cancer.
  • To outline the key clinical applications and areas of use for these PSMA tracers.

Main Methods:

  • Review of currently available and commonly used PSMA-targeting radioligands for PET imaging.
  • Discussion of the established and emerging clinical applications of PSMA PET/CT in prostate cancer management.

Main Results:

  • Several PSMA radioligands are now in routine clinical use, offering improved detection of prostate cancer.
  • PSMA PET/CT demonstrates high efficacy in staging, biochemical recurrence detection, and guiding treatment decisions.

Conclusions:

  • PSMA PET/CT represents a significant advancement in prostate cancer diagnostics, offering precise molecular imaging.
  • The selection of appropriate PSMA tracers depends on the specific clinical scenario and diagnostic question.